Introduction Erythropoiesis-Stimulating Brokers (ESA) are hypothesized to increase cardiovascular mortality in patients with chronic kidney disease. mellitus and estimated glomerular filtration rate. Results At baseline 95.6% of patients with ESA were treated with antihypertensive medication and 73.1% of patients without ESA. No relevant difference in BP was found. During pre-dialysis care patients with ESA used… Continue reading Introduction Erythropoiesis-Stimulating Brokers (ESA) are hypothesized to increase cardiovascular mortality in